Michael Feigh

Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis

Michelle L. Boland, Rhianna C. Laker, KARLY M. MATHER et al. · Nature Metabolism · 2020 · 255 citations · Full text

Life Sciences, Cell Biology, Pharmacology +16

Robust anti‐obesity and metabolic effects of a dual <scp>GLP</scp> ‐1/glucagon receptor peptide agonist in rodents and non‐human primates

Susan Henderson, Anish Konkar, David C. Hornigold et al. · Diabetes Obesity and Metabolism · 2016 · 235 citations · Full text

Life Sciences, Endocrinology, Pharmacology +17

An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)

Michèle Vacca, Ioannis Kamzolas, Lea Mørch Harder et al. · Nature Metabolism · 2024 · 229 citations · Full text

Medicine, Nutrition, Nutritional Sciences +17

Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis

K.S. Tølbøl, Maria Nicoline Baandrup Kristiansen, Henrik H. Hansen et al. · World Journal of Gastroenterology · 2018 · 133 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source

Michelle L. Boland, Denise Oró, K.S. Tølbøl et al. · World Journal of Gastroenterology · 2019 · 129 citations · Full text

Agriculture, Nutrition, Nutritional Sciences +17